WHO Issues A ‘Call To Action’ After Cough Syrup Deaths

Global News

WHO issues a ‘call to action’ after cough syrup deaths

WHO has released an urgent ‘call to action’ to all 194 WHO member states in order to try to prevent, detect and respond to incidences of illegitimate medical products.

Since October 2022, three countries ‒ the Gambia, Indonesia and Uzbekistan ‒ have reported children dying from Acute Kidney Injury (AKI), which resulted from them taking cough syrup containing diethylene glycol and ethylene glycol. WHO issued global medical alerts for each country, leading to products being recalled for public safety and testing by authorities.

In the Gambia, four products made by Maiden Pharmaceuticals were found to have high levels of the chemicals after 66 children died. In Uzbekistan, an analysis conducted by Uzbekistan’s Ministry of Health identified “unacceptable amounts of diethylene glycol and/or ethylene glycol” in products made by Marion Biotech.

As part of its call to action, the WHO has asked regulators to, amongst other things, “detect and remove from circulation in their respective markets any substandard medical products that have been identified in the WHO medical alerts…” and “increase marketing surveillance including risk-based targeting testing for medical products released in their respective markets…”

They have also asked manufacturers to, amongst other things, “only purchase pharmaceutical grade excipients from qualified and bona fide suppliers” and “provide assurance of product quality including through certificates of analyses based on appropriate testing results”.

Contaminated cough syrup leads to WHO Medical Product Alert

The WHO has shared a medical product alert for an additional contaminated cough syrup medicine identified in Africa.

New open innovation hub opened by Astellas for tumour microenvironment research

Astellas Pharma and Mitsui Fudosan have announced that Astellas plans to establish a tumour microenvironment (TME) open innovation hub, intended to open in October 2023.

Jemperli by GSK approved to treat endometrial cancer

GSK has announced that the FDA has approved Jemperli (dostarlimab) in combination with carboplatin and paclitaxel for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (DMMR) or microsatellite instability-high (MSI-H).

Alzheimer’s disease drug Leqembi given full approval by FDA

Japanese Eisai and US-based biotechnology company Biogen have announced that the FDA has given their Alzheimer’s disease drug Leqembi (lecanemab-irmb) full approval through the approval of a supplemental biologics license application.

First over the counter contraceptive pill approved by FDA

FDA has announced that it has approved the Opill (norgestrel) tablet for non-prescription use to prevent pregnancy.

Contaminated cough syrup leads to WHO Medical Product Alert

New open innovation hub opened by Astellas for tumour microenvironment research

Jemperli by GSK approved to treat endometrial cancer

Alzheimer’s disease drug Leqembi given full approval by FDA

First over the counter contraceptive pill approved by FDA

Pharmafocus

Categories

Social Footprints